News Briefs: Agfa invests in RIS integration in Europe
Agfa invests in RIS integration in EuropeAgfa Gevaert, headquartered in Mortsel, Belgium, signed a letter of intent to invest in Quadrat, a medical software company based in Deurle, Belgium. Terms of the agreement have not been disclosed; the deal
Agfa invests in RIS integration in Europe
Agfa Gevaert, headquartered in Mortsel, Belgium, signed a letter of intent to invest in Quadrat, a medical software company based in Deurle, Belgium. Terms of the agreement have not been disclosed; the deal is designed to broaden Agfas integrated PACS/RIS offerings in Europe. Agfa will provide Quadrat with the financial backing, sales and support teams, and customer base to market its RIS and electronic medical record (EMR) software. Quadrat plans to combine PACS and RIS on a single desktop, incorporating images into medAr, its multilingual EMR, which is distributed over the Internet.
In the U.S. market, Agfa plans a midyear launch for Embedded-IS, an option for Impax and Impax Basix that adds RIS functionality to their PACS product (PNN 1/00).
© 2000 Miller Freeman, Inc., a United News & Media company.
- Search again
- Homepage
ASCO: Study Reveals Significant Racial/Ethnic Disparities with PSMA PET Use for Patients with mPCa
May 30th 2025Latinx patients with metastatic prostate cancer were 63 percent less likely than non-Hispanic White patients to have PSMA PET scans, according to a study of 550 patients presented at the American Society of Clinical Oncology (ASCO) conference.
Lunit Unveils Enhanced AI-Powered CXR Software Update
May 28th 2025The Lunit Insight CXR4 update reportedly offers new features such as current-prior comparison of chest X-rays (CXRs), acute bone fracture detection and a 99.5 percent negative predictive value (NPV) for identifying normal CXRs.
New MRI Study Questions Use of Corticosteroid Injections for Knee OA
May 27th 2025Two years after intraarticular knee injections for knee osteoarthritis (OA), study participants who had corticosteroid knee injections had greater OA progression than control patients while the use of hyaluronic acid injections was associated with less OA progression.
